Equities

Theratechnologies Inc

Theratechnologies Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CAD)1.74
  • Today's Change-0.03 / -1.69%
  • Shares traded9.79k
  • 1 Year change+11.54%
  • Beta1.7869
Data delayed at least 15 minutes, as of Nov 12 2024 19:49 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Nov 30 2023202320222021
ASSETS
Cash And Short Term Investments403340
Total Receivables, Net141211
Total Inventory6.072029
Prepaid expenses2.696.327.72
Other current assets, total0.611.953.76
Total current assets637392
Property, plant & equipment, net1.983.092.85
Goodwill, net------
Intangibles, net121524
Long term investments------
Note receivable - long term------
Other long term assets------
Total assets7893119
LIABILITIES
Accounts payable6.991316
Accrued expenses202524
Notes payable/short-term debt000
Current portion long-term debt/capital leases7.71650.46
Other current liabilities, total13114.95
Total current liabilities4711445
Total long term debt511.4556
Total debt596757
Deferred income tax------
Minority interest------
Other liabilities, total0.080.110.09
Total liabilities99116101
SHAREHOLDERS EQUITY
Common stock364339336
Additional paid-in capital231913
Retained earnings (accumulated deficit)(409)(383)(335)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.682.524.41
Total equity(21)(23)18
Total liabilities & shareholders' equity7893119
Total common shares outstanding462424
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.